Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Vanda Pharmaceuticals Inc.    VNDA

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/12/2017 01/13/2017 01/17/2017 01/18/2017 01/19/2017 Date
14.05(c) 14.25(c) 13.45(c) 13.85(c) 13.425 Last
495 878 548 554 627 201 809 185 240 033 Volume
+0.36% +1.42% -5.61% +2.97% -3.07% Change
More quotes
Financials ($)
Sales 2016 147 M
EBIT 2016 -21,8 M
Net income 2016 -20,9 M
Debt 2016 -
Yield 2016 -
Sales 2017 179 M
EBIT 2017 -1,22 M
Net income 2017 1,17 M
Debt 2017 -
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017 554,00
Capi. / Sales2016 4,13x
Capi. / Sales2017 3,40x
Capitalization 609 M
More Financials
Company
Vanda Pharmaceuticals, Inc. engages in the research, development, and commercialization of biopharmaceutical products.It intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder.Its product portfolio includes HETLIOZ,... 
More about the company
Surperformance© ratings of Vanda Pharmaceuticals Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on VANDA PHARMACEUTICALS INC.
01/10 VANDA PHARMACEUTICALS : Research Reports Coverage on Biotech Stocks -- Cara Ther..
01/09 VANDA PHARMACEUTICALS INC. (NASDAQ : VNDA) Files An 8-K Results of Operations an..
01/09 VANDA PHARMACEUTICALS INC. : Results of Operations and Financial Condition, Regu..
01/09 VANDA PHARMACEUTICALS : Reports Preliminary Fourth Quarter and Full Year 2016 Re..
2016 VANDA PHARMACEUTICALS INC. (NASDAQ : VNDA) Files An 8-K Other Events
2016 VANDA PHARMACEUTICALS INC. : Other Events (form 8-K)
2016 VANDA PHARMACEUTICALS : Settles Fanapt® Patent Litigation with Apotex
2016 NETWORKNEWSBREAKS – VANDA PHAR : VNDA) Resolves Patent Litigation Regardin..
2016 VANDA PHARMACEUTICALS INC. : Entry into a Material Definitive Agreement, Financi..
2016 VANDA PHARMACEUTICALS : Settles Fanapt® Patent Litigation with Apotex
More news
Sector news : Bio Therapeutic Drugs
01/13DJNOVARTIS : Supreme Court to Weigh How Soon Firms Can Sell Copycat Biotech Drugs
01/12 Investors in big pharma, biotech look to ride out Trump storm
01/12DJHot Stocks to Watch in the U.S. and Canada
01/10 Regeneron CEO says Amgen not putting patients first in patent dispute
01/09DJCELGENE : Anticipates Slowing Sales Growth for Main Drug Revlimid
More sector news : Bio Therapeutic Drugs
Latest Tweets
01/18Vanda Pharmaceuticals downgraded by Zacks Investment Research to sell.  
01/13What does Jim Kelly think about the #Bills' choice of Sean McDermott for head..
1
01/09Vanda Pharmaceuticals reports preliminary Q4 and FY2016 results and 2017 guid.. 
01/09BRIEF-Vanda Pharmaceuticals says 2016 total revenues are expected to be nearl.. 
01/08Vanda Pharmaceuticals's buy rating reiterated at Jefferies Group. $23.00 PT. .. 
More tweets
Qtime:70
News from SeekingAlpha
01/09 Vanda Pharmaceuticals reports preliminary Q4 and FY2016 results and 2017 guid..
2016 VANDA : Valued Like A Plain Pharma Company, But Isn't One
2016 Tracking John Paulson's Paulson & Company Portfolio - Q3 2016 Update
2016 Healthcare ratings roundup - new coverage
2016 BIOTECH FORUM DAILY DIGEST : DOJ Piles On Biopharma, Investment Case For Gilead ..
Advertisement
Chart VANDA PHARMACEUTICALS INC.
Duration : Period :
Vanda Pharmaceuticals Inc. Technical Analysis Chart | VNDA | US9216591084 | 4-Traders
Full-screen chart
Technical analysis trends VANDA PHARMACEUTI...
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 22,5 $
Spread / Average Target 62%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Mihael Hristos Polymeropoulos President, Chief Executive Officer & Director
H. Thomas Watkins Chairman
James Patrick Kelly Chief Financial Officer, Treasurer & Senior VP
Paolo Baroldi Chief Medical Officer & Senior Vice President
Vincent J. Milano Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
VANDA PHARMACEUTICALS ..-13.17%609
AMGEN, INC.6.54%115 881
GILEAD SCIENCES, INC.0.73%95 028
CELGENE CORPORATION-0.46%89 319
REGENERON PHARMACEUTIC..-1.13%38 280
ACTELION LTD4.58%24 476
More Results